References
1. Waldmann TA. Monoclonal antibodies in diagnosis and therapy.Science . 1991;252(5013):1657-1662.
2. Cheson BD. Rituximab: clinical development and future directions.Expert opinion on biological therapy . 2002;2(1):97-110.
3. Onrust SV, Lamb HM, Balfour JAB. Rituximab. Drugs . 1999;58(1):79-88.
4. Weiner GJ. Rituximab: mechanism of action. Elsevier; 2010:115-123.
5. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of clinical oncology . 2011;29(26):3559-3566.
6. Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.Annals of the rheumatic diseases . 2012;71(3):327-333.
7. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. The Journal of rheumatology . 2012;39(1):125-130.
8. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera®) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. NIHR Health Technology Assessment programme: Executive Summaries . NIHR Journals Library; 2004.
9. Wang H-H, Liu C-W, Li Y-C, Huang Y-C. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.Acta dermato-venereologica . 2015;95(8):928-932.
10. Maneiro R, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Elsevier; 2013:9-17.
11. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).American journal of hematology . 2004;77(2):171-176.
12. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis M-C, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. Journal of Clinical Oncology . 2007;25(22):3344-3349.
13. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia . 2002;16(10):2092.
14. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood . 1997;90(6):2188-2195.
15. Uzun S, Bilgiç Temel A, Akman Karakaş A, et al. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. International journal of dermatology . 2016;55(12):1362-1368.
16. Kimby E. Tolerability and safety of rituximab (MabThera®).Cancer treatment reviews . 2005;31(6):456-473.
17. Maeda R, Kawasaki Y, Ohara S, Suyama K, Hosoya M. Serum sickness with refractory nephrotic syndrome following treatment with rituximab.CEN case reports . 2018;7(1):69-72.
18. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. The oncologist . 2008;13(6):725-732.
19. Awal G, Kaur S, Kaur J, Sharma S. Rituximab-induced serum sickness in pemphigus vulgaris. Journal of the Egyptian Women’s Dermatologic Society . 2018;15(1):54-56.
20. Lunardon L, Payne AS. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. Journal of Allergy and Clinical Immunology . 2012;130(3):800-803.
21. Matsui T, Hidaka M, Kawakita T, et al. Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies.[Rinsho ketsueki] The Japanese journal of clinical hematology . 2009;50(4):304-308.
22. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. JCR: Journal of Clinical Rheumatology . 2007;13(2):94-95.
23. D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine–human chimeric antibody IDEC‐C2B8 (rituximab). Arthritis & Rheumatism: Official Journal of the American College of Rheumatology . 2001;44(7):1717-1718.
24. Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: a systematic review. Elsevier; 2015:334-340.
25. Bayer G, Agier M-S, Lioger B, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European journal of internal medicine . 2019;67:59-64.